The FDA has approved a new Potassium Binder, Veltassa (patiromer for oral suspension) to treat non-life-threatening hyperkalemia. For details see:
The FDA has warned that Veltassa will also bind many other orally administered drugs, and consequently Veltassa comes with a boxed warning that it should not be taken within six hours of other orally administered drugs.
The FDA has also warned that Kayexalate (sodium polystyrene sulfonate, generics Kionex, SPS) may have the same issue, has called for studies of its drug interactions, and advises that for now, out of caution, it too should not be taken within six hours of other orally administered drugs. For details see: